InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.050 -0.001 (-1.96%)+
Announcement
Release
23 Feb 2026 9:31AM
Price at Release
$0.051
Full Release
download
Summary
Argent BioPharma Ltd, an Australia-based biopharmaceutical company, announced the successful delivery of its largest-ever commercial shipment of CannEpil® to Ireland, consisting of 1,000 units valued at approximately AUD 783,000. CannEpil®, which is used for managing Refractory Epilepsy, is fully reimbursed under the Irish National Health Insurance scheme. This milestone reflects the company's capability in executing scaled EU-GMP manufacturing and distribution, enhancing their neurological product portfolio. The delivery was coordinated with Argent's Irish commercial partner, Georgelle Pharma, showcasing Argent BioPharma's strategic growth and market expansion efforts in Europe.
Key Points
  • Largest commercial shipment of CannEpil® to Ireland consisting of 1,000 units valued at AUD 783,000.
  • CannEpil® is reimbursed under the Irish National Health Insurance scheme.
  • CannEpil® is developed to manage seizures associated with Refractory Epilepsy.
  • Argent BioPharma Ltd. (ASX: RGT) facilitated the shipment with its Irish partner, Georgelle Pharma.
  • The shipment demonstrates Argent BioPharma's ability to execute EU-GMP manufacturing and distribution.
  • CannEpil® is part of Argent BioPharma's neurological portfolio, supporting their commercial strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.